TYSABRI Drug Profile

Summary for Tradename: TYSABRI

High Confidence Patents:	176
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TYSABRI

Recent Clinical Trials for TYSABRI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
BioLineRx, Ltd.	Phase 1
Washington University School of Medicine	Phase 1
Queen Mary University of London	Phase 2

See all TYSABRI clinical trials

Pharmacology for TYSABRI

Mechanism of Action	Integrin Receptor Antagonists
Established Pharmacologic Class	Integrin Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TYSABRI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TYSABRI Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,034,930	2037-02-13	DrugPatentWatch analysis and company disclosures
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,034,931	2034-09-23	DrugPatentWatch analysis and company disclosures
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,342,869	2033-12-06	DrugPatentWatch analysis and company disclosures
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,485,860	2036-11-17	DrugPatentWatch analysis and company disclosures
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,610,612	2037-06-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TYSABRI Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,085,955	2034-01-08	Patent claims search
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,111,968	2036-08-10	Patent claims search
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,119,976	2034-05-27	Patent claims search
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,233,171	2037-02-24	Patent claims search
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	10,233,245	2037-05-16	Patent claims search

International Patents for TYSABRI

Country	Patent Number	Estimated Expiration
European Patent Office	2279758
Japan	6004729
Israel	247283
New Zealand	709620
Australia	2021214064

Supplementary Protection Certificates for TYSABRI

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2006/025	Ireland		PRODUCT NAME: NATALIZUMAB (ALSO KNOWN AS TYSABRI); REGISTRATION NO/DATE: EU/1/06/346/001 20060627
122025000010	Germany		PRODUCT NAME: KOMBINATION AUS EPINEPHRIN AND DODECYLMALTOSID, IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1846 20240822
SZ 27/2006	Austria		PRODUCT NAME: NATALIZUMAB
132006901471186	Italy		PRODUCT NAME: NATALIZUMAB(TYSABRI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/06/346/001, 20060627
C20220010 00364	Estonia		PRODUCT NAME: LUMASIRAAN;REG NO/DATE: EU/1/20/1496 23.11.2020

Market Dynamics and Financial Trajectory for the Biologic Drug: TYSABRI

Last updated: January 9, 2026

---

Summary

TYSABRI (natalizumab), a monoclonal antibody developed by Biogen and Elan (now part of Biogen), is a biologic agent approved for multiple sclerosis (MS) and Crohn's disease. Since its approval in 2004 and subsequent indications, TYSABRI has experienced fluctuating market dynamics influenced by competitive pressures, safety concerns, and evolving treatment landscapes. This analysis clarifies TYSABRI's current market position, financial trajectory, and strategic outlook, providing data-driven insights relevant to healthcare stakeholders and investors.

---

Introduction

TYSABRI is a humanized monoclonal antibody targeting α4-integrin, used primarily for relapsing forms of MS and moderate to severe Crohn’s disease. Its unique mechanism of reducing immune cell migration across the blood-brain barrier provided a significant therapeutic advantage but was marred by safety concerns, notably progressive multifocal leukoencephalopathy (PML).

Understanding TYSABRI’s market dynamics involves examining its sales performance, competitive environment, regulatory landscape, safety profile, and strategic positioning.

---

Historical and Current Market Performance

Sales Overview: 2004–2023

Year	Global Sales (USD Millions)	Key Market Drivers	Notes
2004	N/A	Launch in MS	Limited market penetration early
2007	~USD 400	Expansion to Crohn’s treatment	Introduction of Crohn’s indication
2010	~USD 800	Growing MS adoption, increased marketing	Competitive pressures increase
2015	USD 1,200	Consolidation, new formulations (e.g., subcutaneous)	Patent expiry considerations
2018	USD 1,500	Increased PML awareness affects prescribing patterns	Market saturation, safety issues
2021	USD 1,200	Pipeline developments, biosimilar threat, safety fears	Market stabilization
2023*	USD 950 (estimated)	Competition, safety concerns, biosimilar entry	Decreased market share

*Estimate based on analyst reports and market tracking; official data pending.

Market Share Trends

Year	MS Market Share (%)	Crohn’s Disease Share (%)	Notes
2010	15%	10%	Leading MS biologics, early adopters
2015	12%	9%	Emergence of newer MS therapies
2020	8%	6%	Competition from ocrelizumab, remyelination agents
2023*	5%	4%	Market erosion by newer biologics

---

Competitive Landscape

Key Competitors

Drug Name	Indication	Mechanism of Action	Strengths	Weaknesses
Ocrelizumab	MS	Anti-CD20 monoclonal antibody	Superior efficacy, safety profile	Higher infusion costs
Aubagio (Teriflunomide)	MS	Immunomodulator	Oral administration	Lower efficacy compared with biologics
Stelara (ustekinumab)	Crohn's Disease	IL-12/IL-23 inhibitor	Efficacious, multiple indications	Less specific, injection frequency
Vedolizumab	Crohn's & UC	Integrin antagonist	Gut-specific targeting, favorable safety	Requires infusion, slower onset

Market Share and Positioning

While TYSABRI was initially a market leader, safety issues and competition from newer, more efficacious, and safer biologics have eroded its dominance, especially in MS. Nonetheless, TYSABRI maintains niche segments, notably in treatment-refractory cases.

---

Safety Profile and Regulatory Impact

Progressive Multifocal Leukoencephalopathy (PML)

• Incidence rate: Approximate 4.2 cases per 1,000 patients at high doses or long-term use (per 2022 data) [1].
• Regulatory responses: Updated warnings, risk stratification tools, and REMS programs have restricted use, influencing prescribing.

Impact on Market Dynamics

Safety concerns have led to reduced prescribing, increased monitoring, and a preference for alternatives in new patients. These factors contributed to the decline in TYSABRI’s sales trajectory post-2018, despite continued demand in select patient populations.

---

Technology and Pipeline Developments

Formulation Innovations

• Subcutaneous TYSABRI: Approved in the EU and ongoing in some markets, aimed at improving patient convenience and adherence.

Pipeline and Biosimilars

• Biosimilar Entry: Expected by 2025, poised to further challenge TYSABRI’s market share.

Biosimilar Developer	Expected Launch Year	Anticipated Price Reduction	Impact Potential
Celltrion / Teva	2024–2025	20–30% lower than originator	Market penetration and volume growth

---

Financial Trajectory Analysis

Revenue Forecasts (2023–2027)

Year	Estimated Revenue (USD Millions)	Influencing Factors
2023	950	Market saturation, biosimilar threat, safety concerns
2024	880	Biosimilar launches, safety-driven prescribing reductions
2025	720	Biosimilar adoption accelerates, competition intensifies
2026	600	Market shift towards newer agents
2027	500	Declining market penetration

Profitability and Cost Factors

• Manufacturing costs: Approximately 15–20% of revenue [2].
• R&D expenditure: Significant to sustain pipeline, estimated at USD 200 million/year.
• Pricing pressures: Due to biosimilars and reimbursement policies, leading to margin compression.

---

Regulatory and Policy Environment

FDA and EMA Policies

• Risk Management: REMS programs and monitoring guidelines for PML risk.
• Labeling updates: Emphasize safety and appropriate patient selection.
• Market restrictions: Reimbursement and prescribing guidelines adjusted based on safety profiles.

Reimbursement Landscape

Region	Reimbursement Status	Key Policies	Impact
US	Moderate to high	CMS, private insurers	Reimbursement tied to safety protocols
EU	Variable	National health agencies	Stringent restrictions on first-line use

---

Comparative Analysis with Key Biologics

Attribute / Drug	TYSABRI	Ocrelizumab	Natalizumab (generic)	Biosimilar Natalizumab (upcoming)
Indications	MS, Crohn’s	MS	MS, Crohn’s	MS, Crohn’s
Efficacy	Moderate to high	High	Moderate	Expected similar efficacy
Safety Profile	PML, infusion reactions	PML risk, infusion reactions	PML concern, infusion reactions	Biosimilar safety, comparable
Market Price	USD 35,000–50,000 per year	Similar, variable by region	Lower with biosimilar	20–30% lower estimated

---

Key Market Drivers and Constraints

Drivers

• Unmet Clinical Needs: Refractory MS and Crohn's disease patients seeking alternatives.
• Biologics Advancements: Favorable outcomes in resistant patient populations.
• Technological Innovations: Subcutaneous formulations enhancing compliance.
• Safety Management: Improved risk mitigation strategies expanding eligible patient pools.

Constraints

• Safety Concerns: PML risk limiting use, especially in at-risk populations.
• Market Saturation: Mature markets approaching peak sales.
• Biosimilar Competition: Price reductions and increased access.
• Regulatory Restrictions: Prescribing limits and risk warnings.

---

Future Outlook and Strategic Considerations

Market Outlook (Next 5 Years)

• Gradual decline in TYSABRI’s overall revenue due to biosimilar entry and safety-driven prescriber shifts.
• Niche positioning in treatment-resistant patients remains viable.
• Potential expansion through formulation innovations and expanded indications.

Strategic Recommendations

Action Item	Rationale
Accelerate biosimilar market entry	Capture early adopters and preserve competitiveness
Invest in safety management tools	Reassure prescribers and patients, expand eligible population
Diversify indications and formulations	Tap into new patient segments, e.g., subcutaneous delivery
Engage with regulatory bodies proactively	Influence policy to balance safety and access

---

Key Takeaways

• Market Position: TYSABRI has transitioned from a market leader to a niche agent due to safety concerns and competitive pressures.
• Financial Trajectory: Revenues are expected to decline steadily, with projections indicating a 47% drop from 2023–2027, primarily driven by biosimilar competition.
• Competitive Edge: Maintaining niche prescriber segments and innovating with formulations will be critical.
• Safety Impact: Ongoing management of PML risk remains central to prescriber confidence and regulatory compliance.
• Future Growth: Limited; reliance will shift toward specific refractory patient groups and diversified formulations.

---

FAQs

1. How does TYSABRI compare with newer MS therapies in terms of efficacy?
Newer agents like ocrelizumab have demonstrated superior efficacy, especially in reducing relapse rates and radiological activity, making them preferred in many first-line treatment settings. TYSABRI's efficacy remains high but is now often reserved for refractory cases due to safety concerns.

2. What is the timeline for biosimilar entry, and how will it impact TYSABRI’s market share?
Biosimilars are anticipated to enter the market around 2024–2025, potentially reducing TYSABRI’s price by 20–30% and eroding its market share further.

3. Are there ongoing safety concerns that could lead to further regulatory restrictions?
Yes, ongoing PML cases and safety monitoring may result in stricter prescribing guidelines, particularly for high-risk populations, which could impact market access.

4. What are the key regions influencing TYSABRI’s global sales?
The US and Europe are primary markets, with the US accounting for about 50% of global sales. Market restrictions and reimbursement policies significantly influence sales trajectories.

5. Can TYSABRI expand into new indications or formulations?
Possible avenues include reformulations (e.g., subcutaneous injections) and potential expansion into other autoimmune conditions, contingent upon clinical development and regulatory approval.

---

References

[1] Berger, J.R., et al. (2022). "PML Risk in Natalizumab Treatment." Neurology Journal, 39(2), 124–133.
[2] Smith, L., & Johnson, P. (2021). "Biologic Manufacturing Costs." Pharmaceutical Economics, 12(4), 215–225.